Two-Pronged Intracellular Co-Delivery of Antigen and Adjuvant for Synergistic Cancer Immunotherapy

Two-Pronged Intracellular Co-Delivery of Antigen and Adjuvant for Synergistic Cancer Immunotherapy

© 2022 Wiley-VCH GmbH.

Bibliographische Detailangaben
Veröffentlicht in:Advanced materials (Deerfield Beach, Fla.). - 1998. - 34(2022), 21 vom: 09. Mai, Seite e2202168
1. Verfasser: Meng, Junli (VerfasserIn)
Weitere Verfasser: Zhang, Peisen, Chen, Qizhe, Wang, Zihua, Gu, Yuan, Ma, Jie, Li, Wang, Yang, Chen, Qiao, Yuanyuan, Hou, Yi, Jing, Lihong, Wang, Yong, Gu, Zi, Zhu, Lichong, Xu, Haozhen, Lu, Xueguang, Gao, Mingyuan
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2022
Zugriff auf das übergeordnete Werk:Advanced materials (Deerfield Beach, Fla.)
Schlagworte:Journal Article CpG cancer immunotherapy iron oxide nanoparticles membrane fusion nanovaccines Adjuvants, Immunologic Antigens Peptides
LEADER 01000naa a22002652 4500
001 NLM338921850
003 DE-627
005 20231226001743.0
007 cr uuu---uuuuu
008 231226s2022 xx |||||o 00| ||eng c
024 7 |a 10.1002/adma.202202168  |2 doi 
028 5 2 |a pubmed24n1129.xml 
035 |a (DE-627)NLM338921850 
035 |a (NLM)35362203 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a eng 
100 1 |a Meng, Junli  |e verfasserin  |4 aut 
245 1 0 |a Two-Pronged Intracellular Co-Delivery of Antigen and Adjuvant for Synergistic Cancer Immunotherapy 
264 1 |c 2022 
336 |a Text  |b txt  |2 rdacontent 
337 |a ƒaComputermedien  |b c  |2 rdamedia 
338 |a ƒa Online-Ressource  |b cr  |2 rdacarrier 
500 |a Date Completed 27.05.2022 
500 |a Date Revised 27.05.2022 
500 |a published: Print-Electronic 
500 |a Citation Status MEDLINE 
520 |a © 2022 Wiley-VCH GmbH. 
520 |a Nanovaccines have emerged as promising alternatives or complements to conventional cancer treatments. Despite the progresses, specific co-delivery of antigen and adjuvant to their corresponding intracellular destinations for maximizing the activation of antitumor immune responses remains a challenge. Herein, a lipid-coated iron oxide nanoparticle is delivered as nanovaccine (IONP-C/OLP) that can co-deliver peptide antigen and adjuvant (CpG DNA) into cytosol and lysosomes of dendritic cells (DCs) through both membrane fusion and endosome-mediated endocytosis. Such two-pronged cellular uptake pattern enables IONP-C/O@LP to synergistically activate immature DCs. Iron oxide nanoparticle also exhibits adjuvant effects by generating intracellular reactive oxygen species, which further promotes DC maturation. IONP-C/O@LP accumulated in the DCs of draining lymph nodes effectively increases the antigen-specific T cells in both tumor and spleen, inhibits tumor growth, and improves animal survival. Moreover, it is demonstrated that this nanovaccine is a general platform of delivering clinically relevant peptide antigens derived from human papilloma virus 16 to trigger antigen-specific immune responses in vivo 
650 4 |a Journal Article 
650 4 |a CpG 
650 4 |a cancer immunotherapy 
650 4 |a iron oxide nanoparticles 
650 4 |a membrane fusion 
650 4 |a nanovaccines 
650 7 |a Adjuvants, Immunologic  |2 NLM 
650 7 |a Antigens  |2 NLM 
650 7 |a Peptides  |2 NLM 
700 1 |a Zhang, Peisen  |e verfasserin  |4 aut 
700 1 |a Chen, Qizhe  |e verfasserin  |4 aut 
700 1 |a Wang, Zihua  |e verfasserin  |4 aut 
700 1 |a Gu, Yuan  |e verfasserin  |4 aut 
700 1 |a Ma, Jie  |e verfasserin  |4 aut 
700 1 |a Li, Wang  |e verfasserin  |4 aut 
700 1 |a Yang, Chen  |e verfasserin  |4 aut 
700 1 |a Qiao, Yuanyuan  |e verfasserin  |4 aut 
700 1 |a Hou, Yi  |e verfasserin  |4 aut 
700 1 |a Jing, Lihong  |e verfasserin  |4 aut 
700 1 |a Wang, Yong  |e verfasserin  |4 aut 
700 1 |a Gu, Zi  |e verfasserin  |4 aut 
700 1 |a Zhu, Lichong  |e verfasserin  |4 aut 
700 1 |a Xu, Haozhen  |e verfasserin  |4 aut 
700 1 |a Lu, Xueguang  |e verfasserin  |4 aut 
700 1 |a Gao, Mingyuan  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Advanced materials (Deerfield Beach, Fla.)  |d 1998  |g 34(2022), 21 vom: 09. Mai, Seite e2202168  |w (DE-627)NLM098206397  |x 1521-4095  |7 nnns 
773 1 8 |g volume:34  |g year:2022  |g number:21  |g day:09  |g month:05  |g pages:e2202168 
856 4 0 |u http://dx.doi.org/10.1002/adma.202202168  |3 Volltext 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_350 
951 |a AR 
952 |d 34  |j 2022  |e 21  |b 09  |c 05  |h e2202168